Association between use of enhanced recovery after surgery protocols and postoperative complications after gastric surgery for cancer (POWER 4): a nationwide, prospective multicentre study.

Javier Ripollés-Melchor,Ane Abad-Motos, Marcos Bruna-Esteban,María García-Nebreda, Isabel Otero-Martínez,Omar Abdel-Lah Fernández,María P Tormos-Pérez,Gloria Paseiro-Crespo,Raquel García-Álvarez,María A Mayo-Ossorio,Orreaga Zugasti-Echarte,Paula Nespereira-García, Lucia Gil-Gómez,Margarita Logroño-Ejea, Raquel Risco, Felipe C Parreño-Manchado,Silvia Gil-Trujillo, Carmen Benito, Carlos Jericó,María I De-Miguel-Cabrera,Bakarne Ugarte-Sierra, Cristina Barragán-Serrano, José A García-Erce, Henar Muñoz-Hernández, Sabela Del- Río-Fernández, María L Herrero-Bogajo, Alma M Espinosa-Moreno, Vanessa Concepción-Martín,Andrés Zorrilla-Vaca, Laura Vaquero-Pérez,Irene Mojarro, Manuel Llácer-Pérez, Leticia Gómez-Viana, María T Fernández-Martín,Alfredo Abad-Gurumeta,Carlos Ferrando-Ortolà, José M Ramírez-Rodríguez,César Aldecoa

Cirugia espanola(2023)

引用 0|浏览0
暂无评分
摘要
INTRODUCTION:The effectiveness of the Enhanced Recovery After Surgery (ERAS) protocols in gastric cancer surgery remains controversial. METHODS:Multicentre prospective cohort study of adult patients undergoing surgery for gastric cancer. Adherence with 22 individual components of ERAS pathways were assessed in all patients, regardless of whether they were treated in a self-designed ERAS centre. Each centre had a three-month recruitment period between October 2019 and September 2020. The primary outcome was moderate-to-severe postoperative complications within 30 days after surgery. Secondary outcomes were overall postoperative complications, adherence to the ERAS pathway, 30 day-mortality and hospital length of stay (LOS). RESULTS:A total of 743 patients in 72 Spanish hospitals were included, 211 of them (28.4 %) from self-declared ERAS centres. A total of 245 patients (33 %) experienced postoperative complications, graded as moderate-to-severe complications in 172 patients (23.1 %). There were no differences in the incidence of moderate-to-severe complications (22.3% vs. 23.5%; OR, 0.92 (95% CI, 0.59 to 1.41); P = 0.068), or overall postoperative complications between the self-declared ERAS and non-ERAS groups (33.6% vs. 32.7%; OR, 1.05 (95 % CI, 0.70 to 1.56); P = 0.825). The overall rate of adherence to the ERAS pathway was 52% [IQR 45 to 60]. There were no differences in postoperative outcomes between higher (Q1, > 60 %) and lower (Q4, ≤ 45 %) ERAS adherence quartiles. CONCLUSIONS:Neither the partial application of perioperative ERAS measures nor treatment in self-designated ERAS centres improved postoperative outcomes in patients undergoing gastric surgery for cancer. TRIAL REGISTRATION:ClinicalTrials.gov Identifier NCT03865810.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要